(ASRNL) ASR Nederland - Overview
Stock: Insurance, Pensions, Mortgages, Asset Management, Health
Dividends
| Dividend Yield | 5.64% |
| Yield on Cost 5y | 13.35% |
| Yield CAGR 5y | 11.36% |
| Payout Consistency | 91.7% |
| Payout Ratio | 75.8% |
| Risk 5d forecast | |
|---|---|
| Volatility | 19.5% |
| Relative Tail Risk | -2.89% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.64 |
| Alpha | 34.41 |
| Character TTM | |
|---|---|
| Beta | 0.015 |
| Beta Downside | 0.112 |
| Drawdowns 3y | |
|---|---|
| Max DD | 19.40% |
| CAGR/Max DD | 1.06 |
Description: ASRNL ASR Nederland January 03, 2026
ASR Nederland N.V. (ASRNL) is a Dutch insurer offering a broad suite of insurance, pension, and mortgage products to individuals, entrepreneurs, and employers. Its operations are organized into five segments-Non-Life, Life, Asset Management, Distribution & Services, and Holding & Other-covering disability, health, property-casualty, pension, term life, funeral capital, and residential mortgage solutions under brands such as a.s.r., Aegon, Loyalis, TKP, and wijzeringeldzaken.
Key data points (as of FY 2023) include a combined ratio of 95.2% in the Non-Life segment, indicating underwriting profitability, and a Solvency II ratio of 213%, well above the regulatory minimum of 100%. The asset-management arm oversees roughly €30 bn in assets, with a growing allocation to renewable-energy real-estate (wind and solar farms) that aligns with the Netherlands’ 2030 climate targets. The Dutch mortgage market, where ASR holds ~5% market share, is sensitive to the European Central Bank’s policy rate; a 25 bp rate hike in Q4 2023 compressed net interest margins by 12 bps.
If you want to drill down into ASR’s valuation drivers and scenario-based risk metrics, the ValueRay platform provides a concise, data-rich view that can complement your own analysis.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 1.72b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.00 > 0.02 and ΔFCF/TA -0.93 > 1.0 |
| NWC/Revenue: 20.96% < 20% (prev 33.32%; Δ -12.36% < -1%) |
| CFO/TA 0.00 > 3% & CFO 486.0m > Net Income 1.72b |
| Net Debt (7.14b) to EBITDA (14.08b): 0.51 < 3 |
| Current Ratio: 1.96 > 1.5 & < 3 |
| Outstanding Shares: last quarter (212.5m) vs 12m ago -9.81% < -2% |
| Gross Margin: 83.42% > 18% (prev 0.99%; Δ 8243 % > 0.5%) |
| Asset Turnover: 19.44% > 50% (prev 9.67%; Δ 9.77% > 0%) |
| Interest Coverage Ratio: 1.24 > 6 (EBITDA TTM 14.08b / Interest Expense TTM 8.87b) |
Altman Z'' 0.93
| A: 0.04 (Total Current Assets 12.15b - Total Current Liabilities 6.20b) / Total Assets 141.01b |
| B: 0.03 (Retained Earnings 4.22b / Total Assets 141.01b) |
| C: 0.08 (EBIT TTM 11.01b / Avg Total Assets 145.89b) |
| D: 0.05 (Book Value of Equity 6.03b / Total Liabilities 131.15b) |
| Altman-Z'' Score: 0.93 = BB |
Beneish M -1.23
| DSRI: 2.18 (Receivables 72.0m/17.0m, Revenue 28.37b/14.58b) |
| GMI: 1.19 (GM 83.42% / 99.43%) |
| AQI: 0.95 (AQ_t 0.91 / AQ_t-1 0.96) |
| SGI: 1.95 (Revenue 28.37b / 14.58b) |
| TATA: 0.01 (NI 1.72b - CFO 486.0m) / TA 141.01b) |
| Beneish M-Score: -1.23 (Cap -4..+1) = D |
What is the price of ASRNL shares?
Over the past week, the price has changed by +2.03%, over one month by +1.04%, over three months by +8.14% and over the past year by +37.93%.
Is ASRNL a buy, sell or hold?
What are the forecasts/targets for the ASRNL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 64.6 | 3.4% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 80.2 | 28.5% |
ASRNL Fundamental Data Overview January 31, 2026
P/E Trailing = 13.4092
P/E Forward = 10.2145
P/S = 0.7823
P/B = 1.2818
Revenue TTM = 28.37b EUR
EBIT TTM = 11.01b EUR
EBITDA TTM = 14.08b EUR
Long Term Debt = 9.52b EUR (from longTermDebt, last quarter)
Short Term Debt = 115.0m EUR (from shortTermDebt, last fiscal year)
Debt = 9.52b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.14b EUR (from netDebt column, last quarter)
Enterprise Value = 19.94b EUR (12.80b + Debt 9.52b - CCE 2.38b)
Interest Coverage Ratio = 1.24 (Ebit TTM 11.01b / Interest Expense TTM 8.87b)
EV/FCF = 46.71x (Enterprise Value 19.94b / FCF TTM 427.0m)
FCF Yield = 2.14% (FCF TTM 427.0m / Enterprise Value 19.94b)
FCF Margin = 1.51% (FCF TTM 427.0m / Revenue TTM 28.37b)
Net Margin = 6.05% (Net Income TTM 1.72b / Revenue TTM 28.37b)
Gross Margin = 83.42% ((Revenue TTM 28.37b - Cost of Revenue TTM 4.70b) / Revenue TTM)
Gross Margin QoQ = none% (prev -1.94%)
Tobins Q-Ratio = 0.14 (Enterprise Value 19.94b / Total Assets 141.01b)
Interest Expense / Debt = 32.19% (Interest Expense 3.06b / Debt 9.52b)
Taxrate = 20.71% (35.0m / 169.0m)
NOPAT = 8.73b (EBIT 11.01b * (1 - 20.71%))
Current Ratio = 1.96 (Total Current Assets 12.15b / Total Current Liabilities 6.20b)
Debt / Equity = 0.97 (Debt 9.52b / totalStockholderEquity, last quarter 9.86b)
Debt / EBITDA = 0.51 (Net Debt 7.14b / EBITDA 14.08b)
Debt / FCF = 16.73 (Net Debt 7.14b / FCF TTM 427.0m)
Total Stockholder Equity = 9.56b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.18% (Net Income 1.72b / Total Assets 141.01b)
RoE = 17.96% (Net Income TTM 1.72b / Total Stockholder Equity 9.56b)
RoCE = 57.71% (EBIT 11.01b / Capital Employed (Equity 9.56b + L.T.Debt 9.52b))
RoIC = 43.91% (NOPAT 8.73b / Invested Capital 19.88b)
WACC = 14.31% (E(12.80b)/V(22.32b) * Re(5.97%) + D(9.52b)/V(22.32b) * Rd(32.19%) * (1-Tc(0.21)))
Discount Rate = 5.97% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -5.03%
[DCF Debug] Terminal Value 47.61% ; FCFF base≈1.00b ; Y1≈658.1m ; Y5≈300.3m
Fair Price DCF = N/A (negative equity: EV 2.91b - Net Debt 7.14b = -4.23b; debt exceeds intrinsic value)
EPS Correlation: -25.07 | EPS CAGR: -37.87% | SUE: 0.58 | # QB: 0
Revenue Correlation: 63.47 | Revenue CAGR: 22.90% | SUE: 1.40 | # QB: 1
EPS next Year (2026-12-31): EPS=5.89 | Chg30d=+0.167 | Revisions Net=+2 | Growth EPS=+8.5% | Growth Revenue=+2.8%